Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer
Shannon R. Payne
Department of Genetics, University of Washington, Seattle, Washington
Search for more papers by this authorBeth Newman
Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorCorresponding Author
Mary-Claire King
Departments of Genetics and Medicine, Division of Medical Genetics, University of Washington, Seattle, Washington
Departments of Genetics and Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195Search for more papers by this authorShannon R. Payne
Department of Genetics, University of Washington, Seattle, Washington
Search for more papers by this authorBeth Newman
Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina
Search for more papers by this authorCorresponding Author
Mary-Claire King
Departments of Genetics and Medicine, Division of Medical Genetics, University of Washington, Seattle, Washington
Departments of Genetics and Medicine, Division of Medical Genetics, University of Washington, Seattle, WA 98195Search for more papers by this authorAbstract
Germline mutations in BRCA1 predispose to breast and ovarian cancer. Most germline BRCA1 mutations are small insertions, deletions, or single base pair (bp) substitutions. These mutation classes are rarely found as somatic mutations in BRCA1. On the other hand, somatic deletions of multiple mega-base pairs (Mb) including BRCA1, as reflected by loss of heterozygosity, occur frequently in both inherited and sporadic breast and ovarian cancers. To determine whether deletions or rearrangements of hundreds to thousands of bps might contribute to inherited mutation in BRCA1, we developed a Long PCR strategy for screening the entire genomic BRCA1 locus in high-risk families. We evaluated genomic DNA from one high-risk family of European ancestry with BRCA1-linked cancer in which no genomic mutations had been detected using conventional methods. Long PCR revealed a complex mutation, g.12977 ins10 del1039 (based on GenBank L78833), comprising an inverted duplication and deletion in BRCA1 that removes portions of exon 3 and intron 3, including the 5′ splice site for intron 3. As a result of the deletion, exon 3 is skipped, leading to a truncated protein and disease predisposition. Unlike previously reported large germline deletions in BRCA1, neither breakpoint resides within an Alu element. The g.12977 ins10 del1039 mutation was not detected among 11 other breast cancer families, nor among 406 breast cancer patients unselected for family history. Genes Chromosomes Cancer 29:58–62, 2000. © 2000 Wiley-Liss, Inc.
REFERENCES
- Antonarakis SE, the Nomenclature Working Group. 1998. Recommendations for a nomenclature system for human gene mutations. Hum Mutat 11: 1–3.
- Bae YS, Kawasaki I, Ikeda H, Liu LF. 1988. Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci USA 85: 2076–2080.
-
Berchuck A,
Heron K-A,
Carney ME,
Lancaster JM,
Fraser EG,
Vinson VL,
Deffenbaugh AM,
Miron A,
Marks JR,
Futreal PA,
Frank TS.
1998.
Frequency of germline and somatic BRCA1 mutations in ovarian cancer.
Clin Cancer Res
4:
2433–2437.
10.1006/gyno.1998.5270 Google Scholar
- Bieche I, Lidereau R. 1995. Genetic alterations in breast cancer. Genes Chromosomes Cancer 14: 227–251.
- Breast Cancer Information Core. 1999. http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/BIC.
- Devilee P, Cornelisse CJ. 1994. Somatic genetic changes in human breast cancer. Biochem Biophys Acta 1198: 113–130.
- Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, the Breast Cancer Linkage Consortium. 1994. Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692–695.
- Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch E, Rowell SE, King M-C. 1994. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8: 399–404.
- Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Söderkvist P, Terry L, Skolnick MH, Kamb A, Wiseman R. 1994. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120–122.
- Greenblatt MS, Grollman AP, Harris CC. 1996. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res 56: 2130–2136.
- Hall JM, Lee MK, Newman B, Morrow J, Anderson LA, Huey B, King M-C. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250: 1684–1689.
- Henthorn PS, Smithies O, Mager DL. 1990. Molecular analysis of deletions in the human β-globin gene cluster: deletion junctions and locations of breakpoints. Genomics 6: 226–237.
- Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, Jeffreys A. 1995. A somatic BRCA1 mutation in an ovarian tumor. Nat Genet 9: 343–344.
- Hu X, Ray PN, Worton RG. 1991. Mechanisms of tandem duplication in the Duchenne muscular dystrophy gene include both homologous and nonhomologous intrachromosomal recombination. EMBO J 10: 2471–2477.
- Ikeda H. 1986. Bacteriophage T4 DNA topoisomerase mediates illegitimate recombination in vitro. Proc Natl Acad Sci USA 83: 922–926.
- Ketterling RP, Vielhaber EL, Lind TJ, Thorland EC, Sommer SS. 1994. The rates and patterns of deletions in the human Factor IX gene. Am J Hum Genet 54: 201–213.
- Matsushima M, Kobayashi K, Emi M, Saito H, Saito J, Suimori K, Nakamura Y. 1995. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 4: 1953–1956.
- Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS. 1995. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nat Genet 9: 439–443.
- Monnat RJ, Hackmann AFM, Chiaverotti TA. 1992. Nucleotide sequence analysis of human hypoxanthine phosphoribosyltransferase (HPRT) gene deletions. Genomics 13: 777–787.
- Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BJ, Weber BL, Garber JE, Birch JM, Cornelis RS, Kelsell DP, Spurr NK, Smyth E, Haites N, Sobol H, Bignon Y-J, Chang-Claude J, Hamann U, Lindblom A, Borg A, Piver S, Gallion HH, Struewing JP, Whittemore A, Tonin P, Goldgar DE, Easton DF, the Breast Cancer Linkage Consortium. 1995. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 56: 254–264.
- Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET. 1995. The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 35: 51–60.
- Newman B, Mu H, Butler L, Millikan RC, Moorman PG, King M-C. 1998. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279: 915–921.
- O'Connor MB, Malamy MH. 1985. Mapping of DNA gyrase cleavage sites in vivo: oxolinic acid induced cleavages in plasmid pBR322. J Mol Biol 181: 545–550.
- Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst FBL, Hageman S, Arts PJW, Ligtenberg MJL, Meijers-Heijboer H, Klijn JGM, Vasen HFA, Cornelisse CJ, van't Veer LJ, Egbert-Bakker D, van Ommen G-JB, Devilee P. 1997. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17: 341–345.
- Puget N, Torchard D, Serova-Sinilkova OM, Lynch HT, Feunteun J, Lenoir GM, Mazoyer S. 1997. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 57: 828–831.
- Puget N, Stoppa-Lyonnet D, Sinilkova OM, Pages S, Lynch HT, Lenoir GM, Mazoyer S. 1999a. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res 59: 455–461.
- Puget N, Sinilkova OM, Stoppa-Lyonnet D, Audoynaud C, Pages S, Lynch HT, Goldgar D, Lenoir GM, Mazoyer S. 1999b. An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? Am J Hum Genet 64: 300–302.
- Rainville IR, Albertini RJ, Nicklas JA. 1995. Breakpoints and junctional regions of intragenic deletions in the HPRT gene in human T-cells. Som Cell Mol Genet 21: 309–326.
- Rebbeck TR, Couch FJ, Kant J, DeShano M, Peng Y, Chen K, Garber JE, Weber BL. 1997. Genetic heterogeneity in hereditary breast cancer: Role of BRCA1 and BRCA2. Am J Hum Genet 60: 547–553.
- Sander M, Hsieh T-S. 1985. Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site. Nucl Acids Res 13: 1057–1072.
- Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King M-C. 1997. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 60: 1031–1040.
- Sommer SS. 1995. Recent human germline mutation: inferences from patients with hemophilia B. Trends Genet 11: 141–147.
- Swensen J, Hoffman M, Skolnick MH, Neuhausen SL. 1997. Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet 6: 1513–1515.
- Takahashi H, Behbakht K, McGovern PE, Chiu H-C, Couch FJ, Weber B, Friedman LS, King M-C, Furusato M, LiVlosi VA, Menzin AW, Liu PC, Benjamin I, Morgan MA, King SA, Rebane BA, Cardonick A, Mikuta JJ, Rubin SC, Boyd J. 1995. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 55: 2998–3002.
- Wong C, Kazazian HH, Stetten G, Earnshaw WC, Van Keuren ML, Antonarakis SE. 1989. Molecular mechanism in the formation of a human ring chromosome 21. Proc Natl Acad Sci USA 86: 1914–1918.